




RealRate

MEDICINAL PRODUCTS 2020

Navidea Biopharmaceuticals Inc. Rank 49 of 52





RealRate

MEDICINAL PRODUCTS 2020

Navidea Biopharmaceuticals Inc.
Rank 49 of 52



The relative strengths and weaknesses of Navidea Biopharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Navidea Biopharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Navidea Biopharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 173% points.

The company's Economic Capital Ratio, given in the ranking table, is -255%, being 250% points below the market average of -4.3%.

Input Variable	Value in 1000 USD
Assets, Current	2,916
Assets, Non-Current	820
General and Administrative Expense	6,282
Goodwill	385
Liabilities, Current	3,820
Liabilities, Non-Current	512
Other Assets	0
Other Compr. Net Income	0.73
Other Expenses	0.71
Other Liabilities	700
Other Net Income	15
Other Revenues	658
Property, Plant and Equipment, Net	30
Research and Development	5,338

Output Variable	Value in 1000 USD
Liabilities	5,032
Assets	4,151
Expenses	11,621
Revenues	658
Stockholders Equity	-881
Net Income	-10,948
Comprehensive Net Income	-10,948
Economic Capital Ratio	-255%